

FILE 'REGISTRY' ENTERED AT 10:47:58 ON 06 MAR 2009

EXP HEXAMIDINE/CN  
L1 2 S E3  
EXP VITAMIN B3/CN  
L2 3 S E3

FILE 'HCAPLUS' ENTERED AT 10:49:35 ON 06 MAR 2009

1722 S L1  
L3 31873 S L2  
L4 114 S L3 AND L4  
L5 330741 S SKIN OR TOPICAL OR DERMATOLOGICAL  
L6 51 S L5 AND L6  
L7 11 S L7 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L8

```
=> file registry
'REGISTRY' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

```
=> file registry
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.22          0.22
```

```
FILE 'REGISTRY' ENTERED AT 10:47:58 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:  4 MAR 2009  HIGHEST RN 1115640-24-8
DICTIONARY FILE UPDATES:  4 MAR 2009  HIGHEST RN 1115640-24-8
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> exp hexamidine/cn
E1      1      HEXAMIDE, 2,6-DIAMINO-N-GLUCOPYRANOSYL-/CN
E2      1      HEXAMIDE, N,2-DIETHYL-3-OXO-/CN
E3      2 -->  HEXAMIDINE/CN
E4      1      HEXAMIDINE (ANTIEPILEPTIC)/CN
E5      1      HEXAMIDINE (ANTISEPTIC)/CN
E6      1      HEXAMIDINE DIISETHIONATE/CN
E7      1      HEXAMIDINE ISETHIONATE/CN
E8      1      HEXAMINATE/CN
E9      2      HEXAMINE/CN
E10     1      HEXAMINE (HETEROCYCLE)/CN
E11     1      HEXAMINE (POTASSIUM REAGENT)/CN
E12     1      HEXAMINE CHROMATE/CN
```

```
=> s e3
L1      2      HEXAMIDINE/CN
```

```
=> d 11 1-2
```

```
L1      ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2009 ACS on STN
RN      3811-75-4  REGISTRY
ED      Entered STN:  16 Nov 1984
CN      Benzenecarboximidamide, 4,4'-[1,6-hexanediylbis(oxy)]bis- (CA INDEX NAME)
```

OTHER CA INDEX NAMES:

CN Benzamidine, 4,4'-(hexamethylenedioxy)di- (7CI, 8CI)

OTHER NAMES:

CN 1,6-Bis(4-aminophenoxy)hexane

CN 4,4'-(Hexamethylenedioxy)dibenzamidine

CN 4,4-Diamidino-1,6-diphenoxyhexane

CN Desmodine

CN Hexamidine


CN Hexamidine (antiseptic)

MF C20 H26 N4 O2

CI COM

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSNB, DDFU, DRUGU, EMBASE, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

132 REFERENCES IN FILE CA (1907 TO DATE)

19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

133 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN

RN 125-33-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 4,6(1H,5H)-Pyrimidinedione, 5-ethylidihydro-5-phenyl- (CA INDEX NAME)

OTHER NAMES:

CN 2-Deoxyphenobarbital

CN 2-Desoxyphenobarbital

CN 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione

CN 5-Ethylidihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione

CN 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione

CN 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione

CN Hexamidine

CN Hexamidine (antiepileptic)

CN Hexamydin

CN Lepimidin

CN Liskantin

CN Milepsin

CN Misodine

CN Misolyne

CN Mizodin

CN Mizolin

CN Mylepsin

CN Mysedon

CN Mysoline

CN Neurosyn

CN NSC 41701

CN Primaclone

CN Primacone  
 CN Primakton  
 CN Primidon  
 CN Primidone  
 CN Pyrimidone Medi-pets  
 CN Resimatil  
 CN Roe 101  
 CN Sertan  
 DR 8023-71-0, 1340-05-2  
 MF C12 H14 N2 O2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO,  
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,  
 DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPRODUCT,  
 IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, PHAR, PROMT, PS, RTECS\*,  
 SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1587 REFERENCES IN FILE CA (1907 TO DATE)  
 26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1590 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> exp vitamin b3/cn

E1	1	VITAMIN B2-ALDEHYDE-FORMING ENZYME (SCHIZOPHYLLUM COMMUNE ST
		RAIN ATCC 38719 CLONE PBRAF)/CN
E2	1	VITAMIN B2-BUTYRATE/CN
E3	3 -->	VITAMIN B3/CN
E4	1	VITAMIN B4/CN
E5	2	VITAMIN B5/CN
E6	1	VITAMIN B5 CALCIUM SALT/CN
E7	1	VITAMIN B6/CN
E8	1	VITAMIN B6 BIOSYNTHESIS PROTEIN (BACILLUS LICHENIFORMIS STRA
		IN ATCC 14580 GENE PDX1)/CN
E9	1	VITAMIN B6 BIOSYNTHESIS PROTEIN (FRANKIA STRAIN CCI3)/CN
E10	1	VITAMIN B6 BIOSYNTHESIS PROTEIN (THERMOBIFIDA FUSCA STRAIN Y
		X)/CN
E11	1	VITAMIN B6 BIOSYNTHESIS-ASSOCIATED SOR-LIKE PROTEIN (GINKGO
		BILOBA)/CN
E12	1	VITAMIN B6 DIOCTANOATE/CN

=> s e3

L2 3 "VITAMIN B3"/CN

=> d 12 1-3 scan

'1-3' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinecarboxylic acid  
MF C6 H5 N O2  
CI COM



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN  
SAM - Index Name, MF, and structure - no RN  
FIDE - All substance data, except sequence data  
IDE - FIDE, but only 50 names  
SQIDE - IDE, plus sequence data  
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used  
SQD - Protein sequence data, includes RN  
SQD3 - Same as SQD, but 3-letter amino acid codes are used  
SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties  
PPROP - Table of predicted properties  
PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract  
APPS -- Application and Priority Information  
BIB -- CA Accession Number, plus Bibliographic Data  
CAN -- CA Accession Number  
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)  
IND -- Index Data  
IPC -- International Patent Classification  
PATS -- PI, SO  
STD -- BIB, IPC, and NCL  
  
IABS -- ABS, indented, with text labels  
IBIB -- BIB, indented, with text labels  
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:


HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN  $\beta$ -Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-  
MF C9 H17 N O5  
CI COM

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinecarboxamide  
MF C6 H6 N2 O  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file hcplus  
COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

FILE 'HCAPLUS' ENTERED AT 10:49:35 ON 06 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Mar 2009 VOL 150 ISS 11  
FILE LAST UPDATED: 5 Mar 2009 (20090305/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1
L3      1722 L1

=> s l2
L4      31873 L2

=> s l3 and l4
L5      114 L3 AND L4

=> s skin or topical or dermatological
      296639 SKIN
      54653 TOPICAL
      3214 DERMATOLOGICAL
L6      330741 SKIN OR TOPICAL OR DERMATOLOGICAL

=> s l5 and l6
L7      51 L5 AND L6

=> s l7 and (PY<2003 or AY<2003 or PRY<2003)
      22983539 PY<2003
      4504786 AY<2003
      3973776 PRY<2003
L8      11 L7 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l8 1-11 ti abs bib

L8      ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
TI      Novel dosage form comprising modified-release and immediate-release active
      ingredients
AB      A dosage form comprising of a high dose, high solubility active ingredient as
```

modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

AN 2006:100738 HCAPLUS <<LOGINID:20090306>>  
 DN 144:198849  
 TI Novel dosage form comprising modified-release and immediate-release active ingredients  
 IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar  
 PA India  
 SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060024365	A1	20060202	US 2005-134633	20050519 <--
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 20040096499	A1	20040520	US 2003-630446	20030729 <--
PRAI	IN 2002-MU697	A	20020805	<--	
	IN 2002-MU699	A	20020805	<--	
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Skin care compositions comprising hexamidine, zinc oxide and niacinamide on a thin sanitary napkin  
 AB Disclosed is a sanitary napkin for wearing adjacent the pudendal region, having a skin care composition applied thereon, wherein the sanitary napkin has a caliper less than about 5.0 mm. The skin care composition can have about 0.001% to about 0.1% by weight of hexamidine, about 0.001% to about 10% by weight of zinc oxide, about 0.01% to about 10% by weight of niacinamide, and a carrier. Thus, a skin care composition contained hexamidine 0.1, panthenol 0.5, glycerin 0.1, niacinamide/chamomile (Phytoconcentrol Chamomile) 0.5, and a carrier 97.1%, the carrier comprising petrolatum 78.1, behenyl alc. 8.7, Beheneth-10 10.0, and fumed silica 3.2%, resp.

AN 2005:592136 HCAPLUS <<LOGINID:20090306>>  
 DN 143:120595  
 TI Skin care compositions comprising hexamidine, zinc oxide and niacinamide on a thin sanitary napkin  
 IN Warren, Raphael; Hammons, John Lee; Blevins, John Michael; Klofta, Thomas James; Minoguchi, Ryo; Pennington, Regina Leigh; Staudigel, James Anthony; Tanner, Paul Robert; Vatter, Michael Lee  
 PA USA  
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 152,924.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 24

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----



PI	US	20050148962	A1	20050707	US	2004-992430	20041118 <--
	US	20030082219	A1	20030501	US	2002-152924	20020521 <--
	AU	2005265258	A1	20060126	AU	2005-265258	20050621
	CA	2570686	A1	20060126	CA	2005-2570686	20050621
	WO	2006009996	A1	20060126	WO	2005-US21752	20050621
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	EP	1778146	A1	20070502	EP	2005-766062	20050621
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
	CN	1968663	A	20070523	CN	2005-80020084	20050621
	JP	2008503323	T	20080207	JP	2007-518174	20050621
	BR	2005012331	A	20080304	BR	2005-12331	20050621
	AU	2006209374	A1	20060928	AU	2006-209374	20060908
	AU	2006209374	B2	20080214			
	AU	2006209374	B9	20080710			
	IN	2006DN07375	A	20070803	IN	2006-DN7375	20061206
	MX	2006014523	A	20080710	MX	2006-14523	20061213
	KR	2007032704	A	20070322	KR	2006-726863	20061220
	AU	2007200811	A1	20070315	AU	2007-200811	20070223 <--
PRAI	US	2001-968154	B2	20011001	<--		
	US	2002-152924	A2	20020521	<--		
	US	2004-581483P	P	20040621			
	AU	2002-327797	A3	20021001	<--		
	AU	2003-301008	A3	20031216			
	WO	2005-US21752	W	20050621			

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions treatment of chronic inflammatory diseases

AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents,

so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.

AN 2005:369133 HCAPLUS <<LOGINID::20090306>>

DN 142:435774

TI Compositions treatment of chronic inflammatory diseases

IN Shapiro, Howard K.

PA USA

SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 20050090553	A1	20050428	US 2004-924945	20040824 <--
	US 20080234380	A1	20080925	US 2008-70518	20080220 <--
PRAI	US 1992-906909	B2	19920630	<--	
	US 1994-241603	B2	19940511	<--	
	US 1997-814291	B2	19970310	<--	
	US 2000-610073	B2	20000705	<--	
	US 2004-924945	A2	20040824		
OS	MARPAT 142:435774				

L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions comprising an amidine and an alkane polyol

AB The present invention relates to cosmetic compns. containing 0.001 to 10% of an amidine, and 0.01 to 20% of an alkane polyol having a ClogP of from +0.2 to +1.55 and water. The present invention also relates to methods of using such cosmetic compns. to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying a safe and effective amount of such compns. to the skin of a mammal needing such treatment. For example, a moisturizing skin cream/lotion for hand and body skin care was prepared containing Tospearl 144A 1.00, sodium hydroxide 40% solution 0.022, dimethicone and dimethiconol (DC 1503) 1.00, benzyl alc. 0.25, D-panthenol 1.00, polyacrylamide (Sepigel 305) 1.50, fractionated coconut oil 0.40, DL- $\alpha$ -tocopherol acetate 0.25, petrolatum (white soft paraffin) 2.00, iso-Pr isostearate 1.50, behenyl alc. (Stenol 1822A) 0.42, cetyl alc. 95% 0.515, stearic acid 0.10, stearyl alc. (Crodacol S 95) 0.641, PEG-100-stearate (Myrj 59) 0.10, butylated hydroxytoluene 1.00, hexamidine diisethionate 0.10, Et paraben (Nipasol M) 0.07, isohexadecane (Arlamol HD) 3.00, Emulgate PL 68/50 0.20, glycerin 7.00, 1,2-hexanediol 3.00, disodium EDTA 0.10, and water, fragrance, and preservatives to 100%, resp.

AN 2004:1036844 HCAPLUS <<LOGINID::20090306>>

DN 142:11276

TI Compositions comprising an amidine and an alkane polyol

IN Elliott, Russell Phillip; McKay, Barnaby George Robert; Vanoosthuyze, Kristina Emma Inge

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004103290	A2	20041202	WO 2004-US15049	20040514
	WO 2004103290	A3	20060817		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG  
 EP 1477155 A1 20041117 EP 2003-253081 20030516 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 EP 1477157 A1 20041117 EP 2004-252687 20040507  
 EP 1477157 B1 20080319  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 US 20040228820 A1 20041118 US 2004-841193 20040507  
 AT 389382 T 20080415 AT 2004-252687 20040507  
 AU 2004240612 A1 20041202 AU 2004-240612 20040514  
 CA 2524656 A1 20041202 CA 2004-2524656 20040514  
 BR 2004010369 A 20060530 BR 2004-10369 20040514  
 CN 1993102 A 20070704 CN 2004-80013265 20040514  
 JP 2007526873 T 20070920 JP 2006-514357 20040514  
 JP 4217740 B2 20090204  
 MX 2005012322 A 20060130 MX 2005-12322 20051115  
 PRAI EP 2003-253081 A 20030516  
 US 2001-338042P P 20011113 <--  
 WO 2004-US15049 W 20040514

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Skin-protecting compositions to be delivered from absorbent  
 articles  
 AB The present invention relates to a novel composition for efficiently releasing  
 hydrophilic or water-soluble skin care actives from an oleaginous  
 composition. The substantially oleaginous composition of the present invention  
 comprises: (1) at least one skin care active; (2) a release  
 agent having an HLB of at least about 3; and (3) a hydrophobic barrier  
 protectant. The novel release composition may be topically applied to  
 skin using a dispensing means such as an absorbent article, a  
 wipe, a bandage, a pad, a canister, a stick, an aerosol dispenser, a  
 sprayer, and the like. For example, a release composition was formulated  
 containing hexamidine diisethionate 0.1, Beheneth-10 6.3, Petrolatum 72.6,  
 behenyl alc. 17.7, and fumed silica 3.3 %, then deposited on a top sheet  
 of an absorbent article.  
 AN 2004:282815 HCAPLUS <LOGINID::20090306>>  
 DN 140:309487  
 TI Skin-protecting compositions to be delivered from absorbent  
 articles  
 IN Osborne, Scott Edward; Deckner, George Endel; Klofta, Thomas James; Vega,  
 Victor Nicholas  
 PA The Procter & Gamble Company, USA  
 SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 41,266, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

PI US 6716441 B1 20040406 US 1999-466343 19991217 <--  
 ZA 9902000 A 19990913 ZA 1999-2000 19990311 <--  
 TR 200002601 T2 20001221 TR 2000-2601 19990311 <--  
 AT 392906 T 20080515 AT 1999-912417 19990311 <--  
 CA 2393732 A1 20010621 CA 2000-2393732 20001213 <--  
 CA 2393732 C 20051220  
 WO 2001043717 A1 20010621 WO 2000-US33741 20001213 <--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1237535 A1 20020911 EP 2000-984288 20001213 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2003516955 T 20030520 JP 2001-544656 20001213 <--  
 MX 2002005516 A 20020902 MX 2002-5516 20020531 <--  
 US 20040175343 A1 20040909 US 2004-804381 20040319 <--  
 PRAI US 1998-41266 B2 19980312 <--  
 US 1999-466343 A 19991217 <--  
 WO 2000-US33741 W 20001213 <--  
 RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Cosmetic use of a polymer comprising LCST units  
 AB The invention concerns the cosmetic use, in a composition comprising a physiolo-  
 acceptable medium, as an agent for matifying the skin and/or for  
 concealing blemishes and/or for camouflaging pores, of at least one  
 hydrosol, or hydrodispersible polymer comprising hydrosol, or  
 hydrodispersible units and LCST units, the said LCST units having, in  
 water, a demixing temperature (or cloud point) of 5°C to 40°C at a  
 concentration by weight of 1%, the said composition being free of any other  
 compound having  
 an optical effect selected from fillers, ,nacres, pigments, matifying  
 polymers and tightening agents. The invention also concerns the use, in  
 the cosmetic treatment for greasy or combination skin, of a  
 composition containing the said polymer in a physiolo. acceptable medium,  
 excluding  
 any other compound having an optical effect. A matifying cream was prepared  
 containing an aqueous phase comprising Na polyacrylate carrying grafts of  
 Jeffamine M-2005, glycerin, preservatives, EDTA, and demineralized water  
 and an oily phase containing stearyl alc., Cosmacol PSE, Arlacel 165,  
 cyclohexadimethylsiloxane, and preservative.  
 AN 2004:60274 HCAPLUS <<LOGINID:20090306>>  
 DN 140:116974  
 TI Cosmetic use of a polymer comprising LCST units  
 IN Chevalier, Veronique; Lalloret, Florence  
 PA L'Oreal, Fr.  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006872	A1	20040122	WO 2003-EP8484	20030715 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, TD, TG

FR 2842415 A1 20040123 FR 2002-8974 20020716 <--  
 FR 2842415 B1 20050429  
 AU 2003250199 A1 20040202 AU 2003-250199 20030715 <--  
 PRAI FR 2002-8974 A 20020716 <--  
 US 2002-399445P P 20020731 <--  
 WO 2003-EP8484 W 20030715

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor  
 AB An absorbent article, at least a portion of which comprises a skin care composition that comprises an enzyme inhibitor and is at least partially transferred from the article to the skin of a wearer of the article as a result of normal contact, wearer motion and/or body heat. The enzyme inhibitor is transferred to the skin with the skin care composition and is available at the skin/urine and skin/feces interfaces to inhibit enzymic activity on the skin and to reduce or prevent the occurrence of inflammation. Repeated application of similar treated articles to the wearer's skin provides an available source with which the enzyme inhibitor transfers onto the skin continuously over time and accumulates to provide a proactive defense against harmful enzymes for the treatment and/or prevention of diaper dermatitis. A skin care composition was obtained by mixing the following components: 99 parts a melted base composition containing 58 parts petrolatum, 41 parts stearyl alc., and 1 part Aloe extract with 1 part tranexamic acid.

AN 2003:570679 HCAPLUS <<LOGINID::20090306>>  
 DN 139:122826  
 TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor  
 IN Roe, Donald Carroll; Rourke, Francis James; Osborne, Scott Edward  
 PA The Procter & Gamble Company, USA  
 SO U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 623,813.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030139711	A1	20030724	US 2002-323386	20021218 <--
	US 6703536	B2	20040309		
	WO 9945973	A1	19990916	WO 1999-US5311	19990311 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 PRAI US 1998-41266 B2 19980312 <--  
 WO 1999-US5311 A 19990311 <--  
 US 2000-623813 B2 20000908 <--

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Skin care compositions comprising low concentrations of skin treatment agents

AB Skin care compns. that are suitable for application on absorbent articles such as panty liners and interlabial products for delivery of the skin care compns. effective in preventing and/or reducing skin disorders related to erythema, malodor, and skin bacterial infections onto an external or internal area of the skin are described. The composition comprises (a) about 0.001-0.1% by weight of hexamidine; (b) about 0.001-10% by weight of zinc oxide; (c) about 0.01-10% by weight of niacinamide; and (d) a carrier. For example, a skin care composition carrier system contained petrolatum 78.1%, behenyl alc. 8.7%, Beheneth-10 10.0%, and fumed silica 3.2%. A skin care composition was prepared from 97.1% of the carrier system, mixed with 0.7% ZnO Premix, 0.1% hexamidine, 0.5% panthenol, 0.1% glycerin, 1.0% niacinamide, and 0.5% chamomile extract

AN 2003:344402 HCAPLUS <<LOGINID:20090306>>

DN 138:343474

TI Skin care compositions comprising low concentrations of skin treatment agents

IN Warren, Raphael; Blevins, John Michael; Klofta, Thomas James; Minoguchi, Ryo; Pennington, Regina Leigh; Staudigel, James Anthony; Tanner, Paul Robert; Vatter, Michael Lee

PA The Procter & Gamble Company, USA

SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 968,154.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 24

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030082219	A1	20030501	US 2002-152924	20020521 <--
	CA 2462457	A1	20030410	CA 2002-2462457	20021001 <--
	WO 2003028776	A1	20030410	WO 2002-US31135	20021001 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
	AU 2002327797	A1	20030414	AU 2002-327797	20021001 <--
EP	1432457	A1	20040630	EP 2002-763808	20021001 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR	2002013062	A	20040928	BR 2002-13062	20021001 <--
HU	2004001764	A2	20041129	HU 2004-1764	20021001 <--
CN	1561233	A	20050105	CN 2002-819197	20021001 <--
JP	2005504591	T	20050217	JP 2003-532104	20021001 <--
TW	233364	B	20050601	TW 2002-91123298	20021009 <--
US	20030206943	A1	20031106	US 2003-444241	20030523 <--
US	20040170589	A1	20040902	US 2004-789967	20040227 <--
ZA	2004001881	A	20050420	ZA 2004-1881	20040308 <--

	MX	2004003014	A	20040715	MX	2004-3014	20040330 <--
	US	20050129651	A1	20050616	US	2004-992383	20041118 <--
	US	20050148962	A1	20050707	US	2004-992430	20041118 <--
	US	20050154362	A1	20050714	US	2005-59763	20050217 <--
	US	20060062816	A1	20060323	US	2005-222654	20050909 <--
	AU	2006209374	A1	20060928	AU	2006-209374	20060908
	AU	2006209374	B2	20080214			
	AU	2006209374	B9	20080710			
	AU	2007200811	A1	20070315	AU	2007-200811	20070223 <--
	US	20070286876	A1	20071213	US	2007-894165	20070820 <--
PRAI	US	2001-968154	A2	20011001	<--		
	US	2002-152924	A	20020521	<--		
	AU	2002-327797	A3	20021001	<--		
	WO	2002-US31135	W	20021001	<--		
	US	2003-444241	A2	20030523			
	AU	2003-301008	A3	20031216			
	US	2004-789967	A2	20040227			
	US	2004-581483P	P	20040621			

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Cosmetic use of a vinylpyrrolidone-alkene copolymer to modify the appearance of the skin

AB A cosmetic composition for modifying the appearance of the skin contains a copolymer of vinylpyrrolidone with a C10-40 alkene. The composition softens the skin and/or the lips, and/or wipes out rings under the eyes, and hides the skin wrinkles. Thus, an oil-in-water emulsion contained in the oily phase stearyl alc. 1, Cosmacol PSE 1.5, cyclohexadimethyl siloxane 10, Triaccontanyl PVP (Unimer U-6) 3, in the aqueous phase glycerin 5, Hostacerin AMPS 0.4, Dry-Flo 3, xanthan gum 0.2, NaOH 0.01, preservative 0.7, and water to 100%.

AN 2002:634279 HCAPLUS <<LOGINID:20090306>>

DN 137:174546

TI Cosmetic use of a vinylpyrrolidone-alkene copolymer to modify the appearance of the skin

IN Lordi, Kali; Ulrich, Maria; Chevalier, Veronique; Quest, Melanie; Potin, Anthony

PA L'Oreal, Fr.

SO Eur. Pat. Appl., 15 pp.  
CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1232742	A1	20020821	EP 2002-290335	20020212 <--
	EP 1232742	B1	20070808		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20020164294	A1	20021107	US 2001-784210	20010216 <--
	FR 2820972	A1	20020823	FR 2001-2423	20010222 <--
	FR 2820972	B1	20030516		
	AT 369116	T	20070815	AT 2002-290335	20020212 <--
	ES 2290255	T3	20080216	ES 2002-290335	20020212 <--
	JP 2002249414	A	20020906	JP 2002-37425	20020214 <--
	US 20020182158	A1	20021205	US 2002-80066	20020222 <--
	JP 2007145873	A	20070614	JP 2007-67189	20070315 <--
PRAI	FR 2001-784210	A	20010216	<--	
	FR 2001-2423	A	20010222	<--	
	JP 2002-37425	A3	20020214	<--	

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN  
 TI Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum  
 AB A substance for therapeutic, prophylactic, alimentary and cosmetic uses comprises a complex of a medicament or biol. active compound with an organogermanium compound (OGC), with the general formula of  $Lk(OGC)_m(solv)_n$  ( $L$  = medicament,  $solv$  = water or organic solvent,  $k, m = \geq 1, n \geq 0$ ). The complex can be applied for expansion of therapeutic effects spectrum, strengthening of therapeutic effect and decrease of medicament toxicity. An organogermanium compound corresponds to, e.g., 1-germa-2,8,9-trioxa-5-azatricyclo[3.3.3.0.1,5]undecane or 1-germa-2,8-dioxa-5-azabicyclo[3.3.0.1,5]octane in the doses of 0.001-0.1 g per day. The method allows considerable increase of complex pharmacol. activity of medicaments for a wide diversity of diseases and decrease of the medicaments toxicity. For example, complexes of OGC with tranquilizers (diazepam, mezepam, phenazepam, etc.) were more efficient compared to initial tranquilizers concerning decrease of insomnia, suppression of phobia, anxiety, agitation and tensility, and also showed anti-inflammatory, antihypoxic, immunostimulating, repairing, and nootropic effects.

AN 2000:144730 HCAPLUS <<LOGINID:20090306>>

DN 132:189687

TI Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum

IN Soloviev, Evgeny Vladimirovich; Shcherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich; Kotrelev, Mikhail Vladimirovich; Pavlov, Konstantin Vitalevich; Khromova, Nataliya Yurievna; Komalenkova, Nina Georgievna

PA Fr.

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010561	A1	20000302	WO 1998-EP5214	19980817 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9893432	A	20000314	AU 1998-93432	19980817 <--
	EP 1105117	A1	20010613	EP 1998-946360	19980817 <--
	R: CH, DE, FR, GB, LI				
	RU 2233286	C2	20040727	RU 2001-107254	19980817 <--
	US 6451850	B1	20020917	US 2001-763222	20010514 <--
PRAI	WO 1998-EP5214	A	19980817	<--	

OS MARPAT 132:189687

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor

AB An absorbent article, at least a portion of which comprises a skin care composition that comprises an enzyme inhibitor and is at least partially



transferred from the article to the skin of a wearer of the article as a result of normal contact, wearer motion and/or body heat is provided. The enzyme inhibitor is transferred to the skin with the skin care composition and is available at the skin /urine and skin/feces interfaces to inhibit enzymic activity on the skin and to reduce or prevent the occurrence of inflammation. Repeated application of similar treated articles to the wearer's skin provides an available source with which the enzyme inhibitor transfers onto the skin continuously over time and accumulates to provide a proactive defense against harmful enzymes for the treatment and/or prevention of diaper dermatitis. An absorbent article having a topsheet comprising a skin care composition and an enzyme inhibitor was prepared. The composition contained acetohydroxamic acid 1, SEFA cottonate 85, and SEFA behenate 15 parts.

AN 1999:595013 HCAPLUS <<LOGINID:20090306>>

DN 131:219213

TI Disposable absorbent article having a skin care composition containing an enzyme inhibitor

IN Roe, Donald Carroll; Rourke, Francis James; Osborne, Scott Edward

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945973	A1	19990916	WO 1999-US5311	19990311 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9902000	A	19990913	ZA 1999-2000	19990311 <--
	CA 2322503	A1	19990916	CA 1999-2322503	19990311 <--
	AU 9930795	A	19990927	AU 1999-30795	19990311 <--
	BR 9908565	A	20001212	BR 1999-8565	19990311 <--
	TR 200002601	T2	20001221	TR 2000-2601	19990311 <--
	EP 1061962	A1	20001227	EP 1999-912417	19990311 <--
	EP 1061962	B1	20080423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY				
	HU 2001001070	A2	20010730	HU 2001-1070	19990311 <--
	JP 2002505916	T	20020226	JP 2000-535385	19990311 <--
	AT 392906	T	20080515	AT 1999-912417	19990311 <--
	MX 2000008934	A	20010328	MX 2000-8934	20000912 <--
	US 20030139711	A1	20030724	US 2002-323386	20021218 <--
	US 6703536	B2	20040309		
PRAI	US 1998-41266	A	19980312	<--	
	WO 1999-US5311	W	19990311	<--	
	US 2000-623813	B2	20000908	<--	

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT